• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by HUTCHMED (China) Limited

    6/9/26 6:02:51 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCM alert in real time by email
    S-8 1 tm2613054d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 9, 2026

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

     

    HUTCHMED (China) Limited

    (Exact Name of Registrant as specified in its charter)

     

    Cayman Islands Not applicable
    (State or other jurisdiction of (I.R.S. Employer
    incorporation or organization) Identification No.)

     

    48th Floor, Cheung Kong Center  
    2 Queen’s Road Central  
    Hong Kong Not applicable
    Tel: +852 21218200 (Zip Code)

    (Address, including zip code, and telephone number, including area code, of Principal Executive Offices)

     

     

     

    2026 Share Option Scheme

    (Full title of the plan)

     

     

     

    Cogency Global Inc.

    122 East 42nd Street, 18th Floor

    New York, NY 10168

    Tel: (800) 221-0102

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    CHENG Chig Fung, Johnny James C. Lin, Esq.
    Acting Chief Executive Officer and Chief Financial Officer Davis Polk & Wardwell
    Level 18, The Metropolis Tower The Hong Kong Club Building
    10 Metropolis Drive, Hunghom, Kowloon, Hong Kong 3A Chater Road, Central, Hong Kong
    Telephone: +852 2121 8200 Telephone: +852 2533 3300

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x   Accelerated filer ¨
    Non-accelerated filer ¨ (Do not check if a smaller reporting company)   Smaller reporting company ¨
        Emerging Growth Company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Registration of Additional Securities

     

    Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 43,616,756 Ordinary Shares under the 2026 Share Option Scheme. A total of 43,616,756 ordinary shares may be issued under the Registrant’s 2026 Share Option Scheme. These 43,616,756 additional Ordinary Shares are additional securities of the same class as other securities for which registration statements (File No. 333-212406, File No. 333-224391, and No. 333-240180) were filed with the Commission on July 6, 2016, April 23, 2018, and July 30, 2020, respectively.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates the following documents herein by reference:

     

    (a)the contents of the Registrant’s Registration Statement on Form S-8 filed with the Commission on July 6, 2016 (File No. 333-212406);

     

    (b)the contents of the Registrant’s Registration Statement on Form S-8 filed with the Commission on April 23, 2018 (File No. 333-224391);

     

    (c)the contents of the Registrant’s Registration Statement on Form S-8 filed with the Commission on July 30, 2020 (File No. 333-240180);

     

    (d)the Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on March 5, 2026; and

     

    (e)the description of the Registrant’s Ordinary Shares filed as exhibit 2.4 to its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on March 5, 2026, together with any amendment or report filed with the Commission for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement in a document incorporated or deemed to be incorporated by reference in this Registration Statement will be deemed to be modified or superseded to the extent that a statement contained in this Registration Statement or in any other later filed document that also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as so modified or superseded, to be a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    The Exhibits listed on the accompanying Exhibit Index are filed as a part of, or incorporated by reference into, this Registration Statement. (See Exhibit Index below).

     

    EXHIBIT INDEX

     

    Exhibit Description
       
    4.1 Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated by reference to Exhibit 1.1 to the Registrant’s annual report on Form 20-F filed with the Commission on March 3, 2022).
    4.2 Specimen Certificate for Ordinary Shares (incorporated herein by reference to Exhibit 4.3 to Amendment No. 2 to the Registrant’s registration statement on Form F-1 (File No. 333-207447) filed with the Commission on February 11, 2016).
    4.3 Specimen American depositary receipt of the Registrant (incorporated herein by reference to Exhibit 4.1 to Amendment No. 4 to the Registrant’s registration statement on Form F-1 (File No. 333-207447) filed with the Commission on March 4, 2016).

     

     

     

     

    4.4 Form of Deposit Agreement among the Registrant, the depositary and holders and beneficial owners of American depositary receipts (incorporated herein by reference to Exhibit 4.1 to Amendment No. 4 to the Registrant’s registration statement on Form F-1 (File No. 333-207447) filed with the Commission on March 4, 2016).
    4.5 Form of Amendment No. 1 to the Deposit Agreement by and among the Registrant, the depositary and holders and beneficial owners of American depositary receipts (incorporated by reference to Exhibit (a)(2) to Post-Effective Amendment No. 1 to the Registrant’s Registration Statement on Form F-6 (file no. 333-209930) filed with the SEC on May 29, 2019).
    4.6* 2026 Share Option Scheme.
    5.1* Opinion of Conyers Dill & Pearman regarding the validity of the ordinary shares being registered.
    23.1* Consent of Conyers Dill & Pearman (included in Exhibit 5.1).
    23.2* Consent of PricewaterhouseCoopers Zhong Tian LLP, an independent registered accounting firm, regarding the consolidated financial statements of HUTCHMED (China) Limited
    23.3* Consent of PricewaterhouseCoopers Zhong Tian LLP, independent auditors, regarding the consolidated financial statements of Shanghai Hutchison Pharmaceuticals Limited
    24.1* Power of attorney (included on the signature page of this Registration Statement under the caption “Power of Attorney”)
    107* Filing Fee Table

     

    *Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Hong Kong, on June 9, 2026.

     

      HUTCHMED (China) Limited
       
      By: /s/ CHENG Chig Fung, Johnny 
      Name: CHENG Chig Fung, Johnny
      Title: Acting Chief Executive Officer and Chief Financial Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints CHENG Chig Fung, Johnny, as his or her true and lawful attorney-in-fact and agent, with the full power of substitution and re-substitution, for and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them singly, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Dan ELDAR   Chairman of the Board of Directors   June 9, 2026
    Dan ELDAR        
             
    /s/ Weiguo SU   Chief Executive Officer and Chief Scientific Officer, Director   June 9, 2026
    Weiguo SU        
             
    /s/ CHENG Chig Fung, Johnny   Acting Chief Executive Officer and Chief Financial Officer, Director   June 9, 2026
    CHENG Chig Fung, Johnny        
             
    /s/ Edith SHIH   Director   June 9, 2026
    Edith SHIH        
             
    /s/ Ling YANG   Director   June 9, 2026
    Ling YANG        
             
    /s/ Renu BHATIA   Director   June 9, 2026
    Renu BHATIA        
             
    /s/ Chaohong HU   Director   June 9, 2026
    Chaohong HU        
             
    /s/ TAN Shao Weng, Daniel   Director   June 9, 2026
    TAN Shao Weng, Daniel        
             
    /s/ WONG Tak Wai   Director   June 9, 2026
    WONG Tak Wai        

     

     

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of HUTCHMED (China) Limited, has signed this registration statement or amendment thereto in New York, NY on June 9, 2026.

     

      Cogency Global Inc.
      (Authorized U.S. Representative)
       
      By:  /s/ COLLEN A. DE VRIES
        Name: Colleen A. De Vries
        Title: Senior Vice-President

     

     

     

    Get the next $HCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCM

    DatePrice TargetRatingAnalyst
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    5/13/2025Buy → Hold
    HSBC Securities
    11/24/2023Hold → Buy
    Deutsche Bank
    5/4/2022Buy → Hold
    Deutsche Bank
    9/22/2021$46.00Buy → Neutral
    Goldman
    8/3/2021$52.00Buy
    Jefferies
    More analyst ratings

    $HCM
    SEC Filings

    View All

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    6/12/26 6:14:43 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by HUTCHMED (China) Limited

    S-8 - HUTCHMED (China) Ltd (0001648257) (Filer)

    6/9/26 6:02:51 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    6/5/26 6:04:45 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Acting CEO and CFO Cheng Chig Fung

    4 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    5/21/26 6:16:36 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Group General Counsel Nixon Charles George Rupert

    4 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    5/21/26 6:11:26 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and CSO Su Wei-Guo

    4 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    5/21/26 6:07:35 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

    — Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies  — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces results from the Phase III part of the ESLIM-02 study of sovleplenib in patients with warm antibody autoimmune hemolytic anemia ("wAIHA") in China  were presented on Thursday, June 11, 2026 during the European Hematology Association ("EHA") Congress in Stockholm, Sweden. S

    6/11/26 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

    HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA. Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate ("ORR") per RECIST 1.1, as assessed by the

    5/21/26 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. ("Innovent", HKEX:1801) today jointly announce that the New Drug Application (NDA) for the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI) therapy and have not received programmed death receptor-1 ("PD-1") or programmed

    5/21/26 6:00:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HUTCHMED downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded HUTCHMED from Equal-Weight to Underweight and set a new price target of $13.75

    9/22/25 8:24:03 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED downgraded by HSBC Securities

    HSBC Securities downgraded HUTCHMED from Buy to Hold

    5/13/25 3:20:36 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED upgraded by Deutsche Bank

    Deutsche Bank upgraded HUTCHMED from Hold to Buy

    11/24/23 7:13:23 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Leadership Updates

    Live Leadership Updates

    View All

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

    3/5/25 5:00:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Financials

    Live finance-specific insights

    View All

    HUTCHMED to Announce 2024 Final Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025. In addition to the usual English webcast, there will also be a Chin

    2/19/25 3:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

    — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to divest its 45% equity interest in Shang

    1/1/25 5:46:43 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED to Announce 2024 Half-Year Financial Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT /

    6/26/24 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

    SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

    2/13/23 3:54:30 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

    SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

    2/11/22 11:19:49 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by HUTCHMED (China) Limited (Amendment)

    SC 13D/A - HUTCHMED (China) Ltd (0001648257) (Filed by)

    2/7/22 6:12:18 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care